Neuronascent's NNI-362 Shows Promise in Phase 1a Trial for Alzheimer's Disease with Novel Neuron Regeneration Approach
核心洞察
Neuronascent published Phase 1a clinical trial results for NNI-362 in Alzheimer's Research and Therapy, demonstrating the neuron regenerative therapy was well tolerated in healthy aged subjects and reduced plasma pTau181 (搜索) biomarker levels.
The first-in-class investigational therapy targets approximately 6.7 million Alzheimer's patients in the US by promoting adult-born neurons to replace those lost in aging and disease through an orally delivered small molecule.
The company received FDA waiver of fees for canine cognitive disorder (搜索) studies, positioning NNI-362 for proof-of-concept evaluation in a natural disease model that mimics Alzheimer's disease (搜索).
Neuronascent Inc. (搜索) has published positive Phase 1a clinical trial results for its lead investigational therapy NNI-362, marking a significant milestone for the first-in-class neuron regenerative treatment targeting Alzheimer's disease (搜索). The study, published in Alzheimer's Research and Therapy with CEO Dr. Judith Kelleher-Andersson as lead author, demonstrated that NNI-362 was well tolerated in healthy aged subjects and successfully reduced plasma pTau181 (搜索) biomarker levels compared to pre-treatment levels.
Novel Neuron Regeneration Mechanism
NNI-362 represents a groundbreaking approach to treating neurodegenerative diseases by promoting the growth of new neurons to replace those lost during aging and disease progression. "Neuronascent discovered NNI-362 through a novel screening program aimed at identifying small molecules that easily enter the human brain and promote nascent, adult-born neurons to replace those lost in aging and disease," said Kelleher-Andersson.
The orally delivered therapy has received substantial support from the National Institute on Aging (NIA), including funding for the Phase 1a trial. The published study, titled "First in-human study of neuron regenerative therapy NNI-362 to evaluate the safety, pharmacokinetics, and pharmacodynamics in healthy aged population," assessed safety, pharmacokinetics, and plasma biomarkers of Alzheimer's disease (搜索) progression in healthy aged volunteers.
Addressing Significant Unmet Medical Need
Alzheimer's disease (搜索) affects approximately 6.7 million patients in the United States alone, representing a devastating disorder with limited treatment options. "Alzheimer's disease (AD) is a disease of aging and there remains a great unmet need for a disease-modifying treatment," the company noted. The positive pharmacodynamic results from the aged human trial, combined with completed safety and manufacturing studies also supported by the NIA, provide a foundation for advancing to Phase 2 trials in Alzheimer's disease.
Strategic Path Through Canine Model
To demonstrate proof-of-concept for cognitive efficacy, Neuronascent is pursuing studies in Canine Cognitive Disorder (搜索) (CCD), a natural disease model that mimics Alzheimer's disease (搜索). The company has obtained a waiver of the Animal Drug User Fee Act sponsor fee from the FDA, representing the first step toward testing NNI-362 in aged dogs with CCD.
"A rational and viable strategy to demonstrate both proof-of-concept of cognitive efficacy and a path to commercialization of NNI-362 can occur in a natural model that mimics AD, known as Canine Cognitive disorder (搜索)," the company explained. This approach could provide dual benefits, potentially improving the health and lifespan of companion animals while advancing the therapy toward commercialization.
Broader Therapeutic Potential
Beyond Alzheimer's disease (搜索) and canine cognitive disorder (搜索), NNI-362 may offer therapeutic benefits for multiple age-related neurological conditions. "Neuronascent expects that NNI-362 will provide benefit for any number of age-related disorders beyond just Alzheimer's and CCD; including disorders that occur due to loss of neurons in cognitive and motor regions of the brain," according to the company.
Kelleher-Andersson expressed optimism about the therapy's potential impact: "We are thrilled to be able to demonstrate a clean human safety profile and positive effects on biomarkers of progressive disease and now be able to move toward true efficacy evaluation that could improve so many human lives and those of our companion animals."
The Baltimore-based company developed NNI-362 through its proprietary phenotypic screening platform and holds patents for the investigational therapeutic. The therapy's unique mechanism of action, targeting neuron regeneration rather than traditional approaches, positions it as a potentially transformative treatment for neurodegenerative diseases characterized by progressive neuron loss.